AdAlta Ltd (ASX:1AD) has been invited to discuss the development of AD-214 at the 20th Discovery on Target conference in Boston, USA, from September 25 to 28.
Founding chief scientist Prof Mick Foley will talk about the development of the company’s flagship therapeutic, part of its i-body platform targeting fibrotic diseases.
Pre-eminent event for novel drug targets
Organised by the Cambridge Healthtech Institute, Discovery on Target is the industry’s pre-eminent event on novel drug targets and technologies.
Professor Foley’s presentation will be delivered at 8:05 am US EST (10:05 pm AEST) on Thursday, September 28. The topic, 'Discovery and Development Story of AD-214, an Fc-Fusion Protein i-Body for Fibrosis', is included in a stream focused on G-protein coupled receptor (GPCR) biotherapeutics.
GPCRs are a class of drug targets that have proven particularly difficult for antibodies to address and where AdAlta believes its i-body technology offers unique potential.
The presentation will summarise the development of AdAlta’s lead drug candidate, AD-214, from its initial discovery through to the most recent clinical, ex vivo efficacy and dose estimation results for fibrotic diseases.
Healthy newsflow
News flow for AdAlta has been healthy in recent days, with the company only recently receiving results of dose simulation studies supporting the efficacy of AD-214 in fibrotic diseases including Idiopathic Pulmonary Fibrosis at its target intravenous dose regime.
Additionally, CEO Dr Tim Oldham recently talked to Proactive about healthy patient enrolment in the AD-214 Phase 1 extension study, which aimed to assess the flagship drug’s safety – early indications were that it is well tolerated.